Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone

[1] Goldhirsch A(2011)Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736-1747

[2] Wood WC(2011)Adjuvant chemotherapy in luminal breast cancers Breast 20 S128-S131

[3] Coates AS(2009)Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319-1329

[4] Gelber RD(2010)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784-2795

[5] Thürlimann B(1991)Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403-410

[6] Lim E(2007)Significance of pathological evaluation for lymphatic vessel invasion in invasive breast cancer Breast Cancer 14 381-387

[7] Winer EP(2000)Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases Mod Pathol 13 13-18

[8] Goldhirsch A(2007)Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 2127-2132

[9] Ingle JN(2007)Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer Ann Oncol 18 1021-1029

[10] Gelber RD(2011)Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression Breast Cancer Res Treat 130 307-317

[1] Goldhirsch A(2011)Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736-1747

[2] Wood WC(2011)Adjuvant chemotherapy in luminal breast cancers Breast 20 S128-S131

[3] Coates AS(2009)Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319-1329

[4] Gelber RD(2010)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784-2795

[5] Thürlimann B(1991)Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403-410

[6] Lim E(2007)Significance of pathological evaluation for lymphatic vessel invasion in invasive breast cancer Breast Cancer 14 381-387

[7] Winer EP(2000)Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases Mod Pathol 13 13-18

[8] Goldhirsch A(2007)Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 2127-2132

[9] Ingle JN(2007)Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer Ann Oncol 18 1021-1029

[10] Gelber RD(2011)Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression Breast Cancer Res Treat 130 307-317